Celldex Therapeutics, Inc (CLDX) is a publicly traded Healthcare sector company. As of November 4, 2026, CLDX trades at $30.57 with a market cap of $2.33B and a P/E ratio of -7.18. CLDX moved +0.77% today. Year to date, CLDX is +16.84%; over the trailing twelve months it is +25.41%. Its 52-week range spans $14.40 to $45.14. Analyst consensus is strong buy with an average price target of $66.17. Rallies surfaces CLDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for CLDX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $30.57 |
| Market Cap | $2.33B |
| P/E Ratio | -7.18 |
| EPS | $-4.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.14 |
| 52-Week Low | $14.40 |
| Volume | 585.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $158.00K |
| Net Income | $-300.55M |
| Gross Margin | 0.00% |
12 analysts cover CLDX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $66.17.